Is Psychemedics more volatile than Check Cap (USA Stocks:CHEK)?

With Check Cap's market capitalization at a modest 7.4M and a net income loss of 17.6M, potential investors might want to exercise caution before expecting a significant rebound in November. However, the company's substantial cash reserves of 49.84M could provide a buffer for strategic initiatives, possibly offering a glimmer of hope for future growth.

Main Points

To evaluate Check Cap's performance, you can compare its technical and fundamental indicators with those of Psychemedics. This comparison helps assess how market fluctuations impact their stock prices and whether combining them in a portfolio could reduce market risk. A potential strategy is pair trading, where you take a long position in Psychemedics and a short position in Check Cap. For more details, explore our [pair correlation module](#). Now, let's focus on Check Cap's asset utilization. The company currently has a negative asset utilization rate of -0.32%, meaning it loses $0.003169 for every dollar of assets. This indicates inefficiency, as the company isn't effectively generating profit from its assets. In simpler terms, Check Cap isn't making the most of its resources.
Published over three weeks ago
View all stories for Check Cap | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Rifka Kats

When it rains, it pours, and Check Cap has certainly been weathering a storm. As a player in the Diagnostics & Research industry, this company has faced significant challenges, reflected in its financials. With an operating income loss of 19.3 million and a market capitalization of just 7.4 million, the numbers paint a picture of a company struggling to find its footing. Despite a robust current ratio of 13.04X, indicating strong liquidity, the looming probability of bankruptcy at 95.84% raises serious concerns about its long-term viability. As we look towards November, investors are left wondering if Check Cap can turn the tide and stage a comeback. While many traders are steering clear of the healthcare equipment and supplies sector, it's worth taking a closer look at Check Cap to see how it measures up against competitors like Psychemedics. Let's delve into some of the key competitive factors that differentiate Check Cap from Psychemedics and similar companies.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in Check Cap. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its performance over time. Several factors influence the investment perspective on Check Cap, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.

Watch out for price decline

Please consider monitoring Check Cap on a daily basis if you are holding a position in it. Check Cap is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Check Cap stock to be traded above the $1 level to remain listed. If Check Cap stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Check Cap's Liquidity

Check Cap financial leverage refers to using borrowed capital as a funding source to finance Check Cap ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Check Cap financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Check Cap's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Check Cap's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Check Cap's total debt and its cash.

Check Cap Gross Profit

Check Cap Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Check Cap previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Check Cap Gross Profit growth over the last 10 years. Please check Check Cap's gross profit and other fundamental indicators for more details.

What is driving Check Cap Investor Appetite?

Total Debt Breakdown

Lets now check Check Cap total debt. Based on the latest financial disclosure, Check Cap has a Total Debt of 1.33 M. This is 99.95% lower than that of the Health Care Equipment & Supplies sector and 99.86% lower than that of the Health Care industry. The total debt for all United States stocks is 99.97% higher than that of Check Cap.
As for Psychemedics we see total debt of 2.3 M, which is 99.75% lower than that of the Health Care
Sector
928.8 M
CHEK1.33 Million0.14
Sector928.83 Million99.61
PMD2.3 Million0.25
Fortune favors the bold, and for investors eyeing Check Cap, November might just be the time to act. Despite a challenging year, with a 52-week low of 1.12, the company's robust current ratio of 13.04X suggests it has the liquidity to weather short-term challenges. While the diagnostics and research industry can be volatile, Check Cap's market capitalization of 7.43 million and a low debt-to-equity ratio of 0.02% indicate a solid financial foundation. However, potential investors should be cautious of the high probability of bankruptcy at 95.84%, which underscores the inherent risks involved. As the stock hovers near its 52-week low, the potential upside to the target price of 7 could present a compelling opportunity for those willing to take the risk..

Will Check Cap continue to go insane?

Check Cap's stock has experienced significant fluctuations, leaving investors curious about whether these swings will continue. With the mean deviation now at 2.73, there's a hint of reduced volatility, suggesting potential stabilization. However, given the stock's history of erratic behavior, it's uncertain if this calm will persist. Investors should monitor market signals and company news to determine if this is a temporary pause or the beginning of a steadier trend. Check Cap, classified as a potential penny stock, shows low volatility with a skewness of -0.91 and kurtosis of 2.54. While it might present an investment opportunity, penny stocks often carry speculative risks and can be subject to artificial price manipulation. It's crucial to understand both the potential gains and risks. Watch for red flags like spam emails, message board hype, or unreported promotions.
Investigate the backgrounds of company officers before investing in volatile or microcap stocks. While timing your trades perfectly could yield profits, remember that stocks driven by artificial hype often can't sustain elevated prices for long. Sustainable shareholder value comes from genuine performance and strong fundamentals.As we look towards November, Check Cap presents a mixed bag for potential investors. With an analyst target price estimated at $7, there's a hint of optimism, but it's tempered by a possible downside price of just $0.0115, indicating significant risk. The overall analyst consensus to "Hold" suggests a cautious approach, reflecting uncertainty about the company's near-term prospects. While the potential upside price of $4.93 might catch the eye of those willing to take a gamble, it's crucial to weigh this against the company's current valuation metrics. For those considering a stake in Check Cap, it's essential to stay informed and be prepared for volatility as the fiscal year draws to a close in December..

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Check Cap. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com